SCHEMBL20538997

SCHEMBL20538997

C[C@H]1CCN(c2ccc(Cn3cc(C(=O)O)cn3)cn2)C1.[LiH]

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 5/20 0.61
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
MAPK1 P28482 1/20 0.46
BTK Q06187 7/20 0.45
NPC1 O15118 3/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.41
KLK1 P06870 1/20 0.41
ADRA1A P35348 1/20 0.40
EGLN1 Q9GZT9 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20538998 1.00 KLKB1 (0.61) KLKB1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL18795838 0.99 KLKB1 (0.61) KLKB1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL18796211 0.99 KLKB1 (0.61) KLKB1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL24316756 0.91 KLKB1 (0.61) KLKB1RAB9ASMN1; SMN2ALDH1A1KDM4E
Lithium Ion SCHEMBL29536224 0.89 KLKB1 (0.62) KLKB1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL24316749 0.88 KLKB1 (0.61) KLKB1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL18823654 0.87 KLKB1 (0.51) KLKB1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL21953682 0.85 BTK (0.58) KLKB1BTKHSD17B10EGLN1
SCHEMBL20549655 0.84 BTK (0.57) KLKB1BTKHSD17B10EGLN1
SCHEMBL18794977 0.82 BTK (0.58) KLKB1BTKHSD17B10EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10399961-B2 Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-09-03 US disclosed
US-20180305338-A1 HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10399961-B2 Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors KLKB1, BDKRB1, BDKRB2 KLKB1 1/4885RAB9A 2432/4885SMN1; SMN2 4631/4885
US-20180305338-A1 HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, BDKRB1, BDKRB2 KLKB1 1/4885RAB9A 2432/4885SMN1; SMN2 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.